Based on considerable evidence on the safety and efficacy of subcutaneous insulin therapy in the treatment of mild and moderate ketoacidosis [7,14,15,20,22], ISPAD in a scientific guideline recommended that in some critical situations, such as the COVID-19 pandemic, subcutaneous insulin therapy is a valid alternative to IV insulin in patients with non-severe DKA. The gene discussed is INS; the disease is type 2 diabetes mellitus.